AR078182A1 - Combinacion farmaceutica para tratar tumores. composicion farmaceutica. - Google Patents
Combinacion farmaceutica para tratar tumores. composicion farmaceutica.Info
- Publication number
- AR078182A1 AR078182A1 ARP100103379A ARP100103379A AR078182A1 AR 078182 A1 AR078182 A1 AR 078182A1 AR P100103379 A ARP100103379 A AR P100103379A AR P100103379 A ARP100103379 A AR P100103379A AR 078182 A1 AR078182 A1 AR 078182A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- combination
- alkyl
- group
- hydrogen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- -1 1,1-difluoropentyl Chemical group 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 2
- 229930195729 fatty acid Natural products 0.000 abstract 2
- 239000000194 fatty acid Substances 0.000 abstract 2
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N hexane carboxylic acid Natural products CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 abstract 1
- 108091030071 RNAI Proteins 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Una combinacion farmacéutica caracterizado porque comprende: (a) una cantidad eficaz para uso farmacéutico de un agente antitumoral seleccionado del grupo integrado por un agente alquilante, un antimetabolito, un antibiotico, un alcaloide de planta, un fármaco que actua en la diana molecular, una hormona, un complejo de platino, un antisentido, un anticuerpo y ARNi, y (b) una cantidad eficaz para uso farmacéutico de un derivado de ácido graso representado por la formula (1) donde L, M y N son hidrogeno, hidroxi, halogeno, alquilo inferior, hidroxi alquilo (inferior), alcanoíloxi inferior u oxo, donde al menos uno de L y M es un grupo diferente de hidrogeno, y el anillo de cinco miembros puede tener al menos un enlace doble; A es -CH3, o -CH2OH, -COCH2OH, -COOH o un derivado funcional del mismo; B es un enlace simple, -CH2-CH2-, -CH=CH-, -C=C-, -CH2-CH2- CH2-, -CH=CH-CH2-, -CH2-CH=CH-, -C=C-CH2- o -CH2-C=C-; z es el grupo de formulas 2 o enlace simple donde, R4 y R5 son hidrogeno, hidroxi, halogeno, alquilo inferior, alcoxi inferior o hidroxi alquilo (inferior), donde R4 y R5 no son hidroxi y alcoxi inferior al mismo tiempo; R1 es un residuo hidrocarbonado alifático inferior o medio bivalente insaturado o saturado, el cual está sustituido o no sustituido con halogeno, alquilo, hidroxi, oxo, arilo o grupo heterocíclico, y al menos uno del átomo de carbono en el hidrocarburo alifático está opcionalmente sustituido con oxígeno, nitrogeno o azufre; y Ra es un residuo hidrocarbonado alifático inferior o medio saturado o insaturado, el cual está sustituido o no sustituido con halogeno, oxo, hidroxi, alquilo inferior, alcoxi inferior, alcanoíloxi inferior, ciclo alquilo (inferior), ciclo alquiloxi (inferior), arilo, ariloxi, grupo heterocíclico o grupo heterocíclico-oxi; alcoxi inferior; alcanoíloxi inferior; ciclo alquilo (inferior); ciclo alquiloxi (inferior); arilo; ariloxi; grupo heterocíclico; grupo heterocíclico-oxi. Reivindicacion 2: La combinacion segun se describe en la reivindicacion 1, caracterizado porque Ra está sustituido con mono o dihalogeno. Reivindicacion 3: La combinacion segun se describe en la reivindicacion 1, caracterizado porque Z es C=0. Reivindicacion 11: La combinacion segun se describe en la reivindicacion 1, caracterizado porque L es oxo, M es hidrogeno o hidroxi, N es hidrogeno, Z es C=0, Ra está sustituido con mono o dihalogeno. Reivindicacion 15: La combinacion segun se describe en la reivindicacion 1, caracterizado porque dicho derivado de ácido graso es ácido (-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentil)-2-hidroxi-6-oxooctahidrociclopenta[b]piran-5-il]heptanoico, ácido ((-)-7-{(2R,4aR,5R,7aR)-2-[(3S)-1,1-difluoro-3-metilpentil]-2-hidroxi-6-oxooctahidrociclopenta[b]piran-5-il}heptanoico o ácido (-)-7-[(1R, 2R)-2-(4,4-difluoro-3-oxooctil)-5-oxociclopentil]heptanoico o su derivado funcional. Reivindicacion 16: La combinacion segun se describe en la reivindicacion 1, caracterizado porque dicho agente antitumoral es 5-FU o tegaful. Reivindicacion 17: La combinacion segun se describe en la reivindicacion 1, caracterizado porque dicho agente antitumoral es cisplatino.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24301909P | 2009-09-16 | 2009-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078182A1 true AR078182A1 (es) | 2011-10-19 |
Family
ID=43730802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103379A AR078182A1 (es) | 2009-09-16 | 2010-09-16 | Combinacion farmaceutica para tratar tumores. composicion farmaceutica. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9084815B2 (es) |
| EP (1) | EP2477632A4 (es) |
| JP (2) | JP5891168B2 (es) |
| KR (1) | KR101760963B1 (es) |
| CN (2) | CN102481302A (es) |
| AR (1) | AR078182A1 (es) |
| AU (1) | AU2010296307B2 (es) |
| BR (1) | BR112012005896A2 (es) |
| CA (1) | CA2772314A1 (es) |
| IL (1) | IL218392A (es) |
| MX (1) | MX2012003188A (es) |
| NZ (1) | NZ598618A (es) |
| RU (2) | RU2577700C2 (es) |
| SG (2) | SG179153A1 (es) |
| TW (1) | TWI535436B (es) |
| WO (1) | WO2011034210A1 (es) |
| ZA (1) | ZA201201894B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| US20150099802A1 (en) * | 2013-10-03 | 2015-04-09 | Sucampo Ag | Selective tumor treatment |
| JP7176146B1 (ja) | 2022-06-15 | 2022-11-21 | 山崎 明美 | 水路用流向計 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166174A (en) * | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| CA1322749C (en) * | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5221763A (en) * | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| TW224942B (es) * | 1990-04-04 | 1994-06-11 | Adka Ueno Kk | |
| ATE148344T1 (de) | 1990-04-27 | 1997-02-15 | R Tech Ueno Ltd | Verwendung von 15-dehydroxy-16-oxoprostaglandin bei der behandlung von allergischen erkrankungen |
| US5302617A (en) * | 1990-04-27 | 1994-04-12 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio | Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds |
| US5578643A (en) | 1992-05-20 | 1996-11-26 | Loyola University Of Chicago | Protective prostaglandins for use in conjunction with chemotherapeutic agents |
| US5438075A (en) * | 1993-03-30 | 1995-08-01 | Skubitz; Keith M. | Oral glutamine to reduce stomatitis |
| RU2071780C1 (ru) * | 1993-10-11 | 1997-01-20 | Научно-производственное предприятие "Фармэк" | Способ лечения медикаментозных эзофаго-гингиво-стоматитов |
| JPH0770054A (ja) | 1993-08-30 | 1995-03-14 | R Tec Ueno:Kk | 生化学的拮抗および疾患処置剤 |
| CA2150287C (en) * | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| EP0857718B1 (en) * | 1996-06-10 | 2002-08-14 | Sucampo AG | Endothelin antagonist |
| AR030275A1 (es) | 2000-03-24 | 2003-08-20 | Sucampo Pharmaceuticals Inc | Composicion que inhibe la apoptosis y uso de un compuesto 15-ceto-prostaglandina- para producirla |
| US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| US8337891B2 (en) * | 2003-07-03 | 2012-12-25 | Sucampo Ag | Enteric coated composition comprising prostaglandin analogs as chloride channel opener |
| EP2332545A1 (en) | 2005-01-27 | 2011-06-15 | Sucampo AG | Composition for treating central nervous system disorders |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| CN101180096B (zh) * | 2005-03-21 | 2015-04-22 | 苏坎波公司 | 用于治疗粘膜疾病的方法和组合物 |
| US20090012165A1 (en) * | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
-
2010
- 2010-09-15 US US12/882,794 patent/US9084815B2/en not_active Expired - Fee Related
- 2010-09-16 SG SG2012018321A patent/SG179153A1/en unknown
- 2010-09-16 AU AU2010296307A patent/AU2010296307B2/en not_active Ceased
- 2010-09-16 CN CN2010800410970A patent/CN102481302A/zh active Pending
- 2010-09-16 RU RU2012114771/15A patent/RU2577700C2/ru not_active IP Right Cessation
- 2010-09-16 EP EP10817322.0A patent/EP2477632A4/en not_active Withdrawn
- 2010-09-16 CN CN201611061998.1A patent/CN107050458A/zh active Pending
- 2010-09-16 AR ARP100103379A patent/AR078182A1/es unknown
- 2010-09-16 MX MX2012003188A patent/MX2012003188A/es active IP Right Grant
- 2010-09-16 SG SG10201405467PA patent/SG10201405467PA/en unknown
- 2010-09-16 TW TW099131408A patent/TWI535436B/zh not_active IP Right Cessation
- 2010-09-16 RU RU2016103415A patent/RU2016103415A/ru not_active Application Discontinuation
- 2010-09-16 NZ NZ598618A patent/NZ598618A/en not_active IP Right Cessation
- 2010-09-16 BR BR112012005896A patent/BR112012005896A2/pt not_active IP Right Cessation
- 2010-09-16 JP JP2012514010A patent/JP5891168B2/ja active Active
- 2010-09-16 WO PCT/JP2010/066619 patent/WO2011034210A1/en active Application Filing
- 2010-09-16 KR KR1020127009499A patent/KR101760963B1/ko active IP Right Grant
- 2010-09-16 CA CA2772314A patent/CA2772314A1/en not_active Abandoned
-
2012
- 2012-02-29 IL IL218392A patent/IL218392A/en not_active IP Right Cessation
- 2012-03-14 ZA ZA2012/01894A patent/ZA201201894B/en unknown
-
2015
- 2015-06-15 US US14/739,242 patent/US20150272961A1/en not_active Abandoned
-
2016
- 2016-01-07 JP JP2016002010A patent/JP2016056191A/ja active Pending
- 2016-12-07 US US15/371,413 patent/US20170079986A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN107050458A (zh) | 2017-08-18 |
| NZ598618A (en) | 2014-10-31 |
| KR101760963B1 (ko) | 2017-07-24 |
| IL218392A0 (en) | 2012-04-30 |
| CA2772314A1 (en) | 2011-03-24 |
| WO2011034210A1 (en) | 2011-03-24 |
| ZA201201894B (en) | 2012-11-28 |
| AU2010296307A1 (en) | 2012-04-05 |
| JP2016056191A (ja) | 2016-04-21 |
| TWI535436B (zh) | 2016-06-01 |
| US20150272961A1 (en) | 2015-10-01 |
| RU2016103415A (ru) | 2018-11-22 |
| TW201116277A (en) | 2011-05-16 |
| BR112012005896A2 (pt) | 2016-03-15 |
| US20170079986A1 (en) | 2017-03-23 |
| RU2012114771A (ru) | 2013-10-27 |
| EP2477632A4 (en) | 2013-06-12 |
| RU2577700C2 (ru) | 2016-03-20 |
| IL218392A (en) | 2016-05-31 |
| SG179153A1 (en) | 2012-04-27 |
| JP2013504520A (ja) | 2013-02-07 |
| MX2012003188A (es) | 2012-04-30 |
| CN102481302A (zh) | 2012-05-30 |
| US20110064748A1 (en) | 2011-03-17 |
| KR20120081139A (ko) | 2012-07-18 |
| US9084815B2 (en) | 2015-07-21 |
| AU2010296307B2 (en) | 2016-02-11 |
| EP2477632A1 (en) | 2012-07-25 |
| JP5891168B2 (ja) | 2016-03-22 |
| SG10201405467PA (en) | 2014-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060635A1 (es) | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer | |
| CO6300866A2 (es) | Derivado de imidazopiridin - 2 - on | |
| AR051698A1 (es) | Derivados de pirrolo[3,2-d]pirimidin-4-ona como inhibidores de mieloperoxidasa | |
| ECSP12011658A (es) | Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia | |
| EA200901319A1 (ru) | Композиции для назального введения | |
| CR20120190A (es) | INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA | |
| CR20110223A (es) | INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGÍA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT | |
| AR076171A1 (es) | Pirazolopirimidinonas 1,6-disustituidas, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento del alzheimer, epilepsia y otras enfermedades del sistema nervioso central. | |
| BR112012006692A2 (pt) | composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas | |
| BR112012012210B8 (pt) | conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano | |
| BRPI0518613A2 (pt) | compostos, composiÇço farmacÊutica, mÉtodo de preparar uma composiÇço, e, uso de um composto | |
| AR078182A1 (es) | Combinacion farmaceutica para tratar tumores. composicion farmaceutica. | |
| AR078736A1 (es) | Una solucion de droga de taxanos que comprende un regulador de ph y su metodo de preparacion | |
| RU2010138603A (ru) | Композиция для модуляции роста стволовых клеток простагландинами | |
| SG163595A1 (en) | Use of tocotrienol composition for the prevention of cancer | |
| AR035237A1 (es) | Uso de un compuesto 15-cet-prostaglandina para fabricar una composicion para tratar estrenimiento inducido por drogas | |
| AR076263A1 (es) | Composiciones y metodos para tratar cancer. uso. | |
| JP2008528440A5 (es) | ||
| AR055846A1 (es) | Compuesto de prostaglandina y metodo para tratar trastornos del sistema nervioso central | |
| PL2021002T3 (pl) | Kompozycja farmaceutyczna zawierająca medoksomil olmesartanu | |
| BR112013029898A2 (pt) | processo para preparar um óleo de turbina compreendendo um componente de éster | |
| AR042670A1 (es) | Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal | |
| BR112015006370A8 (pt) | composto citotóxico, sua mistura e sal farmaceuticamente aceitável, sal/solvente complexo, metal complexo, exceto um com qualquer de fe2+, fer+, co2+, complexo solvente ou pró-fármico, bem como seu uso e composição o compreendendo | |
| PA8798101A1 (es) | Nuevas composiciones a base de taxoides | |
| ECSP11010856A (es) | Composición farmacéutica sólida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |